메뉴 건너뛰기




Volumn 36, Issue 5, 2015, Pages 3471-3482

Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials

Author keywords

Cetuximab; Electrolyte disorders; Meta analysis; Panitumumab

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; PANITUMUMAB; ELECTROLYTE; EPIDERMAL GROWTH FACTOR RECEPTOR; MAGNESIUM;

EID: 84929964336     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2983-9     Document Type: Article
Times cited : (52)

References (50)
  • 1
    • 40849147041 scopus 로고    scopus 로고
    • EGFR antagonists in cancer treatment
    • COI: 1:CAS:528:DC%2BD1cXjt1ahsL4%3D, PID: 18337605
    • Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160–74.
    • (2008) N Engl J Med , vol.358 , pp. 1160-1174
    • Ciardiello, F.1    Tortora, G.2
  • 2
    • 2142714017 scopus 로고    scopus 로고
    • Monoclonal antibodies as therapeutic agents for cancer
    • COI: 1:CAS:528:DC%2BD2cXjs1antbY%3D, PID: 15120666
    • Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004;5:292–302.
    • (2004) Lancet Oncol , vol.5 , pp. 292-302
    • Harris, M.1
  • 3
    • 18844370441 scopus 로고    scopus 로고
    • Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy
    • COI: 1:CAS:528:DC%2BD2MXjsVCjtbk%3D, PID: 15846113
    • Pal SK, Pegram M. Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs. 2005;16:483–94.
    • (2005) Anticancer Drugs , vol.16 , pp. 483-494
    • Pal, S.K.1    Pegram, M.2
  • 4
    • 0034779291 scopus 로고    scopus 로고
    • The EGFR as a target for anticancer therapy—focus on cetuximab
    • Baselga J. The EGFR as a target for anticancer therapy—focus on cetuximab. Eur J Cancer. 2001;37(Supplement 4):16–22.
    • (2001) Eur J Cancer , vol.37 , pp. 16-22
    • Baselga, J.1
  • 5
    • 3242720345 scopus 로고    scopus 로고
    • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    • COI: 1:CAS:528:DC%2BD2cXlvFGitbk%3D, PID: 15269313
    • Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.
    • (2004) N Engl J Med , vol.351 , pp. 337-345
    • Cunningham, D.1    Humblet, Y.2    Siena, S.3    Khayat, D.4    Bleiberg, H.5    Santoro, A.6
  • 6
    • 34548289390 scopus 로고    scopus 로고
    • FDA drug approval summary: panitumumab (Vectibix)
    • COI: 1:CAS:528:DC%2BD2sXntVyns7Y%3D, PID: 17522246
    • Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: panitumumab (Vectibix). Oncologist. 2007;12:577–83.
    • (2007) Oncologist , vol.12 , pp. 577-583
    • Giusti, R.M.1    Shastri, K.A.2    Cohen, M.H.3    Keegan, P.4    Pazdur, R.5
  • 7
    • 78650694719 scopus 로고    scopus 로고
    • First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
    • COI: 1:CAS:528:DC%2BC3MXhtF2ktw%3D%3D, PID: 21169060
    • Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol. 2011;12:30–7.
    • (2011) Lancet Oncol , vol.12 , pp. 30-37
    • Gatzemeier, U.1    von Pawel, J.2    Vynnychenko, I.3    Zatloukal, P.4    de Marinis, F.5    Eberhardt, W.E.6
  • 8
    • 69149107165 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
    • PID: 19622511
    • Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.
    • (2009) Ann Intern Med , vol.151 , pp. 264-269
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 9
    • 84859160601 scopus 로고    scopus 로고
    • Operative versus nonoperative treatment for acute Achilles tendon rupture: a meta-analysis based on current evidence
    • PID: 22159659
    • Jiang N, Wang B, Chen A, Dong F, Yu B. Operative versus nonoperative treatment for acute Achilles tendon rupture: a meta-analysis based on current evidence. Int Orthop. 2012;36:765–73.
    • (2012) Int Orthop , vol.36 , pp. 765-773
    • Jiang, N.1    Wang, B.2    Chen, A.3    Dong, F.4    Yu, B.5
  • 10
    • 0022992740 scopus 로고
    • Meta-analysis in clinical trials
    • COI: 1:STN:280:DyaL2s7gsVamtA%3D%3D, PID: 3802833
    • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
    • (1986) Control Clin Trials , vol.7 , pp. 177-188
    • DerSimonian, R.1    Laird, N.2
  • 12
    • 0028659004 scopus 로고
    • Operating characteristics of a rank correlation test for publication bias
    • COI: 1:STN:280:DyaK2Mzgs1GrtQ%3D%3D, PID: 7786990
    • Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
    • (1994) Biometrics , vol.50 , pp. 1088-1101
    • Begg, C.B.1    Mazumdar, M.2
  • 13
    • 0030922816 scopus 로고    scopus 로고
    • Bias in meta-analysis detected by a simple, graphical test
    • COI: 1:STN:280:DyaK2svls1KjtA%3D%3D, PID: 9310563
    • Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
    • (1997) BMJ , vol.315 , pp. 629-634
    • Egger, M.1    Smith, G.D.2    Schneider, M.3    Minder, C.4
  • 15
    • 41549167668 scopus 로고    scopus 로고
    • A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
    • COI: 1:STN:280:DC%2BD1c3gsFWgsQ%3D%3D, PID: 18272912
    • Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol. 2008;19:734–8.
    • (2008) Ann Oncol , vol.19 , pp. 734-738
    • Tol, J.1    Koopman, M.2    Rodenburg, C.J.3    Cats, A.4    Creemers, G.J.5    Schrama, J.G.6
  • 16
    • 79959337678 scopus 로고    scopus 로고
    • Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
    • COI: 1:CAS:528:DC%2BC3MXnslShtLk%3D, PID: 21641636
    • Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377:2103–14.
    • (2011) Lancet , vol.377 , pp. 2103-2114
    • Maughan, T.S.1    Adams, R.A.2    Smith, C.G.3    Meade, A.M.4    Seymour, M.T.5    Wilson, R.H.6
  • 17
    • 84859403854 scopus 로고    scopus 로고
    • Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial
    • COI: 1:CAS:528:DC%2BC38XlsFehtr8%3D, PID: 22474202
    • Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307:1383–93.
    • (2012) JAMA , vol.307 , pp. 1383-1393
    • Alberts, S.R.1    Sargent, D.J.2    Nair, S.3    Mahoney, M.R.4    Mooney, M.5    Thibodeau, S.N.6
  • 18
    • 84892713818 scopus 로고    scopus 로고
    • Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer
    • COI: 1:CAS:528:DC%2BC3sXhslOrtbfP, PID: 24244261
    • Siena S, Van Cutsem E, Li M, Jungnelius U, Romano A, Beck R, et al. Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. PLoS One. 2013;8:e62264.
    • (2013) PLoS One , vol.8 , pp. e62264
    • Siena, S.1    Van Cutsem, E.2    Li, M.3    Jungnelius, U.4    Romano, A.5    Beck, R.6
  • 19
    • 44249111440 scopus 로고    scopus 로고
    • EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
    • COI: 1:CAS:528:DC%2BD1cXntVOltrk%3D, PID: 18390971
    • Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2311–9.
    • (2008) J Clin Oncol , vol.26 , pp. 2311-2319
    • Sobrero, A.F.1    Maurel, J.2    Fehrenbacher, L.3    Scheithauer, W.4    Abubakr, Y.A.5    Lutz, M.P.6
  • 20
    • 84899900161 scopus 로고    scopus 로고
    • Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial
    • COI: 1:CAS:528:DC%2BC2cXlvVSnu70%3D, PID: 24717919
    • Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014;15:601–11.
    • (2014) Lancet Oncol , vol.15 , pp. 601-611
    • Primrose, J.1    Falk, S.2    Finch-Jones, M.3    Valle, J.4    O'Reilly, D.5    Siriwardena, A.6
  • 21
    • 78149250536 scopus 로고    scopus 로고
    • Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
    • COI: 1:CAS:528:DC%2BC3cXhsF2rtLzI, PID: 20921465
    • Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705.
    • (2010) J Clin Oncol , vol.28 , pp. 4697-4705
    • Douillard, J.Y.1    Siena, S.2    Cassidy, J.3    Tabernero, J.4    Burkes, R.5    Barugel, M.6
  • 22
    • 78149239651 scopus 로고    scopus 로고
    • Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
    • COI: 1:CAS:528:DC%2BC3cXhsF2rtLzJ, PID: 20921462
    • Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706–13.
    • (2010) J Clin Oncol , vol.28 , pp. 4706-4713
    • Peeters, M.1    Price, T.J.2    Cervantes, A.3    Sobrero, A.F.4    Ducreux, M.5    Hotko, Y.6
  • 23
    • 59949102930 scopus 로고    scopus 로고
    • A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
    • COI: 1:CAS:528:DC%2BD1MXjsVCjs74%3D, PID: 19114685
    • Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672–80.
    • (2009) J Clin Oncol , vol.27 , pp. 672-680
    • Hecht, J.R.1    Mitchell, E.2    Chidiac, T.3    Scroggin, C.4    Hagenstad, C.5    Spigel, D.6
  • 24
    • 34147103678 scopus 로고    scopus 로고
    • Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
    • PID: 17470858
    • Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–64.
    • (2007) J Clin Oncol , vol.25 , pp. 1658-1664
    • Van Cutsem, E.1    Peeters, M.2    Siena, S.3    Humblet, Y.4    Hendlisz, A.5    Neyns, B.6
  • 25
    • 84888129994 scopus 로고    scopus 로고
    • Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial
    • COI: 1:CAS:528:DC%2BC3sXhslOjs7%2FP, PID: 24231627
    • Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol. 2013;14:1326–36.
    • (2013) Lancet Oncol , vol.14 , pp. 1326-1336
    • Kim, E.S.1    Neubauer, M.2    Cohn, A.3    Schwartzberg, L.4    Garbo, L.5    Caton, J.6
  • 26
    • 37649022615 scopus 로고    scopus 로고
    • Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer
    • COI: 1:CAS:528:DC%2BD1cXnsFOgsg%3D%3D, PID: 18089875
    • Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol. 2007;25:5777–84.
    • (2007) J Clin Oncol , vol.25 , pp. 5777-5784
    • Butts, C.A.1    Bodkin, D.2    Middleman, E.L.3    Englund, C.W.4    Ellison, D.5    Alam, Y.6
  • 27
    • 80051742422 scopus 로고    scopus 로고
    • Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407
    • COI: 1:CAS:528:DC%2BC3MXhtFyqu7nI, PID: 21747084
    • Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol. 2011;29:3120–5.
    • (2011) J Clin Oncol , vol.29 , pp. 3120-3125
    • Govindan, R.1    Bogart, J.2    Stinchcombe, T.3    Wang, X.4    Hodgson, L.5    Kratzke, R.6
  • 28
    • 65349116059 scopus 로고    scopus 로고
    • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
    • COI: 1:CAS:528:DC%2BD1MXltlaqurs%3D, PID: 19410716
    • Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373:1525–31.
    • (2009) Lancet , vol.373 , pp. 1525-1531
    • Pirker, R.1    Pereira, J.R.2    Szczesna, A.3    von Pawel, J.4    Krzakowski, M.5    Ramlau, R.6
  • 29
    • 77949891126 scopus 로고    scopus 로고
    • Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099
    • COI: 1:CAS:528:DC%2BC3cXktF2lsbk%3D, PID: 20100966
    • Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010;28:911–7.
    • (2010) J Clin Oncol , vol.28 , pp. 911-917
    • Lynch, T.J.1    Patel, T.2    Dreisbach, L.3    McCleod, M.4    Heim, W.J.5    Hermann, R.C.6
  • 30
    • 33144461661 scopus 로고    scopus 로고
    • Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study
    • PID: 16314626
    • Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology G. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646–54.
    • (2005) J Clin Oncol , vol.23 , pp. 8646-8654
    • Burtness, B.1    Goldwasser, M.A.2    Flood, W.3    Mattar, B.4    Forastiere, A.A.5    Eastern Cooperative Oncology, G.6
  • 31
    • 51649085865 scopus 로고    scopus 로고
    • Platinum-based chemotherapy plus cetuximab in head and neck cancer
    • COI: 1:CAS:528:DC%2BD1cXhtFWrsrnI, PID: 18784101
    • Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.
    • (2008) N Engl J Med , vol.359 , pp. 1116-1127
    • Vermorken, J.B.1    Mesia, R.2    Rivera, F.3    Remenar, E.4    Kawecki, A.5    Rottey, S.6
  • 32
    • 84879785532 scopus 로고    scopus 로고
    • Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
    • COI: 1:CAS:528:DC%2BC3sXptFGjtrk%3D, PID: 23746666
    • Vermorken JB, Stohlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14:697–710.
    • (2013) Lancet Oncol , vol.14 , pp. 697-710
    • Vermorken, J.B.1    Stohlmacher-Williams, J.2    Davidenko, I.3    Licitra, L.4    Winquist, E.5    Villanueva, C.6
  • 33
    • 84878365339 scopus 로고    scopus 로고
    • Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
    • COI: 1:CAS:528:DC%2BC3sXntV2ms7c%3D, PID: 23623280
    • Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14:627–37.
    • (2013) Lancet Oncol , vol.14 , pp. 627-637
    • Crosby, T.1    Hurt, C.N.2    Falk, S.3    Gollins, S.4    Mukherjee, S.5    Staffurth, J.6
  • 34
    • 84876992498 scopus 로고    scopus 로고
    • Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
    • COI: 1:CAS:528:DC%2BC3sXmt1Oksb0%3D, PID: 23594787
    • Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:481–9.
    • (2013) Lancet Oncol , vol.14 , pp. 481-489
    • Waddell, T.1    Chau, I.2    Cunningham, D.3    Gonzalez, D.4    Okines, A.F.5    Okines, C.6
  • 35
    • 77957552916 scopus 로고    scopus 로고
    • Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial
    • COI: 1:CAS:528:DC%2BC3cXht1eqsbzJ, PID: 20679619
    • Okines AF, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol. 2010;28:3945–50.
    • (2010) J Clin Oncol , vol.28 , pp. 3945-3950
    • Okines, A.F.1    Ashley, S.E.2    Cunningham, D.3    Oates, J.4    Turner, A.5    Webb, J.6
  • 36
    • 77955914277 scopus 로고    scopus 로고
    • Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205
    • COI: 1:CAS:528:DC%2BC3cXhtFSksb3O, PID: 20606093
    • Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605–10.
    • (2010) J Clin Oncol , vol.28 , pp. 3605-3610
    • Philip, P.A.1    Benedetti, J.2    Corless, C.L.3    Wong, R.4    O'Reilly, E.M.5    Flynn, P.J.6
  • 37
    • 84876951761 scopus 로고    scopus 로고
    • Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
    • COI: 1:CAS:528:DC%2BC3sXmt1OntLw%3D, PID: 23594786
    • Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:490–9.
    • (2013) Lancet Oncol , vol.14 , pp. 490-499
    • Lordick, F.1    Kang, Y.K.2    Chung, H.C.3    Salman, P.4    Oh, S.C.5    Bodoky, G.6
  • 38
    • 84883858492 scopus 로고    scopus 로고
    • Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
    • COI: 1:CAS:528:DC%2BC3sXht1entLrF, PID: 23733761
    • Baselga J, Gomez P, Greil R, Braga S, Climent MA, Wardley AM, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2013;31:2586–92.
    • (2013) J Clin Oncol , vol.31 , pp. 2586-2592
    • Baselga, J.1    Gomez, P.2    Greil, R.3    Braga, S.4    Climent, M.A.5    Wardley, A.M.6
  • 39
    • 80155178194 scopus 로고    scopus 로고
    • The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis
    • COI: 1:STN:280:DC%2BC3MbjsFShuw%3D%3D, PID: 21402620
    • Balagula Y, Wu S, Su X, Lacouture ME. The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. Ann Oncol. 2011;22:2366–74.
    • (2011) Ann Oncol , vol.22 , pp. 2366-2374
    • Balagula, Y.1    Wu, S.2    Su, X.3    Lacouture, M.E.4
  • 40
    • 84918832390 scopus 로고    scopus 로고
    • Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials
    • Cui R, Chu L, Liu ZQ, Xiao YY, Zhu XL, Chen YJ et al. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials. Int J Cancer. 2014.
    • (2014) Int J Cancer
    • Cui, R.1    Chu, L.2    Liu, Z.Q.3    Xiao, Y.Y.4    Zhu, X.L.5    Chen, Y.J.6
  • 41
    • 84858695125 scopus 로고    scopus 로고
    • Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies
    • COI: 1:CAS:528:DC%2BC38XktVaitr4%3D, PID: 21843103
    • Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf. 2012;11 Suppl 1:S9–19.
    • (2012) Expert Opin Drug Saf , vol.11 , pp. S9-S19
    • Petrelli, F.1    Borgonovo, K.2    Cabiddu, M.3    Ghilardi, M.4    Barni, S.5
  • 42
    • 0034722889 scopus 로고    scopus 로고
    • The EGF receptor family as targets for cancer therapy
    • COI: 1:CAS:528:DC%2BD3MXhsF2ku7k%3D, PID: 11426640
    • Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550–65.
    • (2000) Oncogene , vol.19 , pp. 6550-6565
    • Mendelsohn, J.1    Baselga, J.2
  • 43
    • 18844473781 scopus 로고    scopus 로고
    • Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
    • COI: 1:CAS:528:DC%2BD3cXktVWisbw%3D, PID: 10815919
    • Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000;6:1936–48.
    • (2000) Clin Cancer Res , vol.6 , pp. 1936-1948
    • Bruns, C.J.1    Harbison, M.T.2    Davis, D.W.3    Portera, C.A.4    Tsan, R.5    McConkey, D.J.6
  • 44
    • 18544369466 scopus 로고    scopus 로고
    • Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family
    • COI: 1:CAS:528:DC%2BD38XktVKgtro%3D, PID: 12032568
    • Schlingmann KP, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet. 2002;31:166–70.
    • (2002) Nat Genet , vol.31 , pp. 166-170
    • Schlingmann, K.P.1    Weber, S.2    Peters, M.3    Niemann Nejsum, L.4    Vitzthum, H.5    Klingel, K.6
  • 45
    • 34547700632 scopus 로고    scopus 로고
    • Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia
    • COI: 1:CAS:528:DC%2BD2sXoslOns7Y%3D, PID: 17671655
    • Groenestege WM, Thebault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007;117:2260–7.
    • (2007) J Clin Invest , vol.117 , pp. 2260-2267
    • Groenestege, W.M.1    Thebault, S.2    van der Wijst, J.3    van den Berg, D.4    Janssen, R.5    Tejpar, S.6
  • 46
    • 84880622301 scopus 로고    scopus 로고
    • Evaluation of hypomagnesemia: lessons from disorders of tubular transport
    • COI: 1:CAS:528:DC%2BC38Xhslymt7jN, PID: 23201160
    • Dimke H, Monnens L, Hoenderop JG, Bindels RJ. Evaluation of hypomagnesemia: lessons from disorders of tubular transport. Am J Kidney Dis. 2013;62:377–83.
    • (2013) Am J Kidney Dis , vol.62 , pp. 377-383
    • Dimke, H.1    Monnens, L.2    Hoenderop, J.G.3    Bindels, R.J.4
  • 48
    • 20144381957 scopus 로고    scopus 로고
    • Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    • COI: 1:CAS:528:DC%2BD2MXjt1Ckuro%3D, PID: 15677699
    • Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803–10.
    • (2005) J Clin Oncol , vol.23 , pp. 1803-1810
    • Chung, K.Y.1    Shia, J.2    Kemeny, N.E.3    Shah, M.4    Schwartz, G.K.5    Tse, A.6
  • 50
    • 84876483964 scopus 로고    scopus 로고
    • Liu B,Zou Z. Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: a meta-analysis
    • Chen P WL, Li H, Liu B,Zou Z. Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: a meta-analysis. Oncol Lett. 2013;1915–20.
    • (2013) Oncol Lett , pp. 1915-1920
    • Chen, P.W.L.1    Li, H.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.